Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neuroscience
Biotech
Novartis inks $175M option deal for Sironax’s BBB tech
If Novartis decides to buy the platform, Sironax will have the chance to make up to $175 million in upfront and near-term payments.
Gabrielle Masson
Jul 9, 2025 10:29am
AstraZeneca culls neuroscience meds in Q1 clear-out
Apr 29, 2025 7:08am
GSK pens $2.5B pact for ABL's blood-brain barrier-bypassing tech
Apr 7, 2025 7:00am
Clario continues acquisition spree with imaging firm NeuroRx
Mar 18, 2025 6:50am
Biohaven's biopolar med fails pivotal test
Mar 3, 2025 5:14pm
Newleos unveils with $93M and 4 ex-Roche programs
Feb 13, 2025 12:00am